Home
overview

The global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market.

With that in mind, SMi is proud to present the 3rd Annual Ophthalmic Drugs Conference taking place on the 19th-20th of November 2019, in London.

As Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

This three-day agenda offers you peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more.

We look forward to welcoming you to the conference in November.
 

Early registration is strongly advised to avoid disappointment.
 

 

  • Explore novel approaches to delivery of ocular drugs
  • Understand late-stage clinical development programs through real-world examples
  • Delve into novel delivery methods for ophthalmic drugs via implants lenses and punctal plugs
  • Learn how micro-dosing technologies are being used for the treatment of ocular disease
  • New for 2019: focus day on the challenges of drug delivery through a complex barrier

 

 

Key Job Titles:

Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Clinical Trial Managers, Medical Officers of:

Ophthalmology
Ophthalmic devices
Drug Delivery
Drug discovery
Research and development
Clinical development
Quality assurance
Immunology, Inflammation and Allergies
Market Access
Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.

 

Aerie Pharmaceuticals; Aero Pump Gmbh; Alimera Sciences; Alimera Sciences Limited; Allergan Ltd; Annexin Pharmaceuticals AB; Biozep AS; Boehringer Ingelheim Pharma GmbH & Co. KG; Casebia Therapeutics; Elasmogen Ltd; Experimentica Ltd; Gyroscope Therapeutics ; Janssen R&D, JNJ; King khaled eye specialist hospital ; Kingston University; LABORATOIRES THEA; Medicines and Healthcare Products Regulatory Agency; Medivis; Medpharm; MeiraGTx; MHRA; Nanoptima Ltd; NEMERA; NightstarX; Novartis Pharma Schweiz Ag; Optceutics Limited; Ora Europe Ltd; Oxstem; Queens University Belfast; Roche; Roche Products Ltd; Roechling; RXGen; Santen Incorporated; Silgan Dispensing; Similasan; Similasan AG; Spark Therapeutics; Topivert; Topivert Ltd; TwoXAR; University of Oxford; West Pharmaceutical Services;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

Naj  Sharif

Naj Sharif, Vice President, Santen Incorporated
View Bio

9:10 Launch of Rocklatan in the USA

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

  • An industry outlook of drug development and advances in the ROCK inhibitor class of drugs
  • The first PG combination product approved by the FDA and the outlook for Europe approval
  • Future outlook for glaucoma treatment
  • 9:50 Novel Treatment Modalities for Managing Ocular Hypertension (OHT) and Glaucoma

    Naj  Sharif

    Naj Sharif, Vice President, Santen Incorporated
    View Bio

  • Compliance issues with topical ocular medications for OHT/Glaucoma treatment
  • Omidenepag Isopropyl (OMDI): novel non-prostaglandin EP2 receptor agonist for treating OHT/Glaucoma
  • Use of "PRESERFLO MicroShunt" (formerly known as the InnFocus MicroShunt) to lower and control intraocular pressure in OHT/Glaucoma patients
     
  • 10:30 Morning Coffee

    11:00 Biomechanical Modulation Therapy: A druggable alternative to corneal stem cell transplantation

    Che  Connon

    Che Connon, Professor of Tissue Engineering, Newcastle University
    View Bio

  • Chemical burns to the ocular surface affect tissue stiffness
  • The corneal stem cell niche has specific biomechanical requirements to retain stem cells
  • Restoring the correct biomechanical state of the corneal stem cell niche following wounding improve healing
  • Biomechanical modulation therapy is a new treatment paradigm for corneal epithelial wounds
  • 11:40 Regulatory outlook on ocular drug clinical development

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

  • Current regulatory perspectives for clinical approval of ophthalmic drugs
  • Focus on rare diseases – orphan designation, conditional approvals and exceptional circumstances
  • Regulatory considerations for biologics and biosimilars
  • Regulatory considerations for gene therapy agents
     
  • 12:20 Networking Lunch

    13:20 Establishing efficacy of gene therapy in preclinical ocular models

    Giedrius Kalesnykas

    Giedrius Kalesnykas, President and Chief Executive Officer, Experimentica Ltd
    View Bio

  • Ocular tissue distribution of different viral vectors
  • Imaging modalities to detect reporter gene expression in vivo
  • Immunosuppression for gene therapy in preclinical ocular models
  • 14:00 Clinical Development of Voretigene Neparvovec-ryzl, a gene therapy for Biallelic RPE65 Mutation-associated Inherited Retinal Disease: An Update

    Daniel  Chung

    Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
    View Bio

  • To understand basic characteristics of RPE65 disease
  • To understand the clinical development process of voretigene neparvovec-ryzl
  • To understand the development/rationale of the primary phase 3 endpoint
  • 14:40 Afternoon Tea

    15:10 Gene Therapy for Inherited Retinal Diseases

  • Latest trends in gene therapy for Inherited Retinal Diseases
  • Clinical Trial Endpoints for Inherited Retinal Diseases
  • Regulatory guidance/thresholds for Clinical Trial Endpoints in Inherited Retinal Diseases
     
  • Aniz Girach

    Aniz Girach, Chief Medical Officer, ProQR Therapeutics
    View Bio

    Daniel  Chung

    Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
    View Bio

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

    Virginia Calder

    Virginia Calder, Reader in Ocular Immunology, UCL Institute of Ophthalmology
    View Bio

    15:50 Antisense Oligonucleotides for Inherited Retinal Diseases

    Aniz Girach

    Aniz Girach, Chief Medical Officer, ProQR Therapeutics
    View Bio

  • Antisense oligonucleotides have shown much promise in Ph1/2 Clinical Trials in LCA10
  • Visual Acuity and other efficacy endpoints have improved in an interim analysis
  • Overview of the data available from clinical trials
     
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    Naj  Sharif

    Naj Sharif, Vice President, Santen Incorporated
    View Bio

    9:10 Transforming the future of eye care

    Parisa Zamiri

    Parisa Zamiri, Global Head of clinical development in Ophthalmology, Novartis Pharmaceutical inc

  • Designing the clinical trials of the future
  • Providing Individualized medicine
  • Understand the burden of disease, tailor treatment to patients
  • Delivering novel therapeutics

     

  • 9:50 Use of experimental models to identify potential anti-inflammatory drugs in allergic conjunctivitis and uveitis

    Virginia Calder

    Virginia Calder, Reader in Ocular Immunology, UCL Institute of Ophthalmology
    View Bio

  • Mouse models of conjunctival (EIC) and retinal (EAU) inflammatory disease will be described
  • Monitoring conjunctival CD4+T cell subsets, conjunctival fibrosis and identification of ALDH pathways
  • Effects of novel therapies on leukocyte migration, CD4+T cell subsets in EAU, and the effect of blocking H4R and LTB4.
  • 10:30 Morning Coffee

    11:00 Molded Polymer Dosage Forms - Current and Future Applications in Ophthalmic Drug Delivery

    James Arps

    James Arps, Director, ProMed Pharma
    View Bio

  • Review of resorbable and biodurable polymers for ophthalmic drug delivery –benefits and disadvantages
  • Design considerations for molded and extruded ophthalmic dosage forms
  • Examples of novel implants and devices for drug delivery to the eye
     
  • 11:40 The need of an in vitro ocular model for preclinical testing of intraocular formulations

    Sahar Awwad

    Sahar Awwad, CSO, Optceutics Ltd
    View Bio

  • The need for longer acting formulations
  • Challenges during preclinical development-use of animal models, lack of models in the pharmacopeia and biopharmaceutical formulation challenges
  • Development and capabilities of the PK-Eye with a few case studies
     
  • 12:20 Networking Lunch

    13:20 The Applications of AI in Drug Discovery

    Aaron C. Daugherty

    Aaron C. Daugherty, Vice President of Discovery, TwoXAR
    View Bio

  • Unpacking the conceptual to practical applications of AI
  • Where is AI being used in healthcare today
  • Guidance on decision making about AI, and real-world examples of AI-driven results
  • How twoXAR’s computational drug discovery platform has led to the discovery of new drugs
  • 14:00 Using AI for early detection of Diabetic Retinopathy

    William Dallman

    William Dallman, Clinical Development Manager, Eyenuk
    View Bio

  • Introduction to Eyenuk
  • Why screen?
  • Importance of detection
  • How can we help?
  • 14:40 Afternoon Tea

    15:10 Accelerating the development of intraocular medicines with the PK-Eye

    Steve Brocchini

    Steve Brocchini, Academic Staff , UCL School of Pharmacy and UCL Institute of Ophthalmology

  • Biological therapies have revolutionized the treatment of blinding diseases during the last 2 decades
  • Pharmaceutical development relies on the use of in vitro models to develop new medicines
  • The PK-Eye provides a unique platform for ophthalmic drug development
  • PK-Eye capabilities include accelerated preclinical dosage form characterisation and optimization
  • 15:50 Chairman’s Closing Remarks and Close of Day Two

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    Naj  Sharif

    Naj Sharif, Vice President, Santen Incorporated
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA

    9:10 Safety and Efficacy of a Novel Intracapsular Drug Delivery Platform

    Michael Burr

    Michael Burr, Vice President of Product Development, iVeena

  • iVeena has developed an intracapsular drug delivery platform that enables bi-directional drug delivery to anterior and posterior eye segments.
  • The initial platform technology application is IVMED-20, a bioerodible dexamethasone delivery implant placed during cataract surgery to prophylax cystoid macular edema, as well as, control inflammation and pain from the procedure.
  • IVMED-20 is intended for cataract patients at high risk of developing cystoid macular edema, including concurrent: diabetic retinopathies & edemas, epiretinal membranes, macular hole, retinal vein occlusions, and uveitis.
  • IVMED-20 has been studied in an ex-US clinical study. This proof of concept study, albeit not statistically powered, suggest the ability to safely control inflammation, and reduce retinal thickening, without anti-inflammatory eye drops.
  • 9:50 Barriers to Posterior Segment Drug Delivery

    Clive G Wilson

    Clive G Wilson, Professor of Pharmaceutics, University of Strathclyde

  • New drugs offer the promise of stopping or even reversing age-related sight impairment but need appropriate methods of delivery.
  • Overview of the key issues in systemic or topical administration of drugs for the back of the eye
  • Understand how the ageing eye alters drug distribution from a reservoir.
  • Examine tactical approaches to overcoming barrier issues and examine advantages and shortfalls of approaches.
  • 10:30 Morning Coffee

    11:00 Drug delivery to the posterior segment of the eye

  • Novel delivery methods that are currently in the pipeline
  • What are the main challenges in delivery to the back of the eye?
  • How will we tackle these challenges and learn from recent R&D?
  • Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA

    Clive G Wilson

    Clive G Wilson, Professor of Pharmaceutics, University of Strathclyde

    Virginia Calder

    Virginia Calder, Senior Lecturer, Ocular Biology, Ucl Hospitals

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    11:40 Regulatory perspectives on novel ocular drug delivery

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA

  • Novel ocular drug delivery and the regulatory framework – clinical considerations
  • Combination products, devices and borderline products
  • 12:10 Networking Lunch

    13:10 Sustained drug release for managing ocular hypertension and glaucoma

    Jinzhong Zhang

    Jinzhong Zhang, Vice President, Graybug Vision Inc

  • Long-lasting therapeutics that effectively lower and maintain IOP remain a substantial unmet medical need
  • Available ocular drug delivery platforms
  • Choice of administration routes: intracameral, subconjunctival or intravitreal injection
  • An injectable formulation of a beta-adrenergic antagonist prodrug for sustained reduction of intraocular pressure
  • 13:50 Age-related eye diseases: how can drug delivery research help?

    Raid Alany

    Raid Alany, Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University

  • Delivery of drugs and biologics to the front and back of the eye is a challenge
  • Dry eye, glaucoma and AMD are prevalent amongst the aging population; they require pharmaceutical intervention using drug(s) that need to be formulated
  • Novel pharmaceutical formulation and drug delivery strategies could offer solutions to unmet ophthalmic needs
  • 14:30 Afternoon Tea

    15:00 An update on ocular drug delivery pathways: from cornea to retina

    Borja Salvador Culla

    Borja Salvador Culla, Consultant Ophthalmology, Centro de Oftamologia Barraquer

  • Difficulties in delivering therapeutical levels of medication to the eye
  • Current pathways of drug delivery to the eye
  • New drug delivery devices: contact lenses, intravitreal implants, depot…
  • What will the future bring us?
  • 15:40 Chairman’s Closing Remarks and Close of Day Three

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA

    +

    FEATURED SPEAKERS

    Aaron C. Daugherty

    Aaron C. Daugherty

    Vice President of Discovery, TwoXAR
    Aniz Girach

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Borja Salvador Culla

    Borja Salvador Culla

    Consultant Ophthalmology, Centro de Oftamologia Barraquer
    Clive G Wilson

    Clive G Wilson

    Professor of Pharmaceutics, University of Strathclyde
    Daniel  Chung

    Daniel Chung

    Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
    Giedrius Kalesnykas

    Giedrius Kalesnykas

    President and Chief Executive Officer, Experimentica Ltd
    James Arps

    James Arps

    Director, ProMed Pharma
    Jinzhong Zhang

    Jinzhong Zhang

    Vice President, Graybug Vision Inc
    Michael Burr

    Michael Burr

    Vice President of Product Development, iVeena
    Mitchell De Long

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Naj  Sharif

    Naj Sharif

    Vice President, Santen Incorporated
    Parisa Zamiri

    Parisa Zamiri

    Global Head of clinical development in Ophthalmology, Novartis Pharmaceutical inc
    Peter Morgan Warren

    Peter Morgan Warren

    Medical Assessor, MHRA
    Peter Morgan Warren

    Peter Morgan Warren

    Medical Assessor, MHRA
    Raid Alany

    Raid Alany

    Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University
    Sahar Awwad

    Sahar Awwad

    CSO, Optceutics Ltd
    Virginia Calder

    Virginia Calder

    Senior Lecturer, Ocular Biology, Ucl Hospitals
    Virginia Calder

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology
    William Dallman

    William Dallman

    Clinical Development Manager, Eyenuk

    Aaron C. Daugherty

    Vice President of Discovery, TwoXAR
    Aaron C. Daugherty

    Aaron Daugherty is the Vice President of Discovery at twoXAR, a pharmaceutical company that is harnessing large biomedical datasets and Artificial Intelligence to accelerate the discovery and development of first-in-class drugs. One of twoXAR's first employees, Aaron has helped build twoXAR's drug discovery AI and now leads the Discovery Science team's efforts to expand that software, while simultaneously using it to discover potential treatments across a wide range of diseases. Aaron's earned his PhD in genetics from Stanford University. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in biology from the University of Richmond.

    Andrew A. Radin

    Co-Founder and CEO, TwoXAR
    Andrew A.  Radin

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Aniz Girach

    Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK).
    After having spent 11 years in the NHS, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 22 years industry experience in roles with Merck (as their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development, and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease. In his role as Chief Medical Officer at Nightstar Therapeutics, he oversaw the development of their gene therapy programmes for inherited retinal diseases. In addition to being an Honorary Professor at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at ProQR Therapeutics, leading the development of RNA therapeutics for inherited retinal diseases.
    He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for 5 peer-reviewed journals, including Eye and IOVS. He has edited 4 books and published over 100 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings.
    His special interests are Medical Retina, Vitreomacular interface abnormalities and Gene/RNA therapy for inherited retinal diseases.

    Borja Salvador Culla

    Consultant Ophthalmology, Centro de Oftamologia Barraquer
    Borja Salvador Culla

    Che Connon

    Professor of Tissue Engineering, Newcastle University
    Che  Connon

    Professor Connon’s research team seeks to engineer functional replacement and temporary 'bridge' tissues using a modular approach while also developing model systems to study physiological and pathophysiological corneal tissue formation. He is currently working with smart (cell responsive) biomaterials, characterizing the mechanical and geometric environment of the corneal stem cell niche and 3D printing the corneal stroma. Professor Connon has received continuous UK government research funding since 2007 and has published over 70 papers in international journals and has edited several books in corneal regenerative medicine, stem cell bioprocessing and hydrogels in tissue engineering. Recent highlights from 2019 include “4D corneal tissue engineering” within Advanced Functional Materials (IF=13.3) and “Engineering the corneal stem cell niche” within Nature Communications (IF=12.4).

    Clive G Wilson

    Professor of Pharmaceutics, University of Strathclyde
    Clive G Wilson

    Daniel Chung

    Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
    Daniel  Chung

    Dr. Chung is the Medical Strategy Lead- Ophthalmology for Spark Therapeutics and the company’s inherited retinal disease and ophthalmology expert and resource. He also served as Spark’s Medical Affair Ophthalmic Lead and the Clinical Development Ophthalmic Lead. Prior to joining Spark Therapeutics, he was a senior investigator at the FM Kirby Center for Molecular Ophthalmology at the Scheie Eye Institute at the Perelman School of Medicine of the University of Pennsylvania, working in retinal gene therapy and transfer. Concurrently, he served as the scientific advisor on the RPE65 gene therapy study team at the Children’s Hospital of Philadelphia (CHOP). He was the PI and first author for the RPE65 natural history study and the Multi-luminance Mobility Test (MLMT) validation study. Dr. Chung earned his medical degree from the New York Institute of Technology College of Osteopathic Medicine and completed his residency in Akron, Ohio. He then completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, with additional training in retinal gene therapy at the National Eye Institute/NIH in Bethesda, MD. As the medical strategy lead for ophthalmology, he works in the areas of medical affairs, clinical development and operations, pre-clinical studies, patient advocacy, commercial and marketing and business development.

    Giedrius Kalesnykas

    President and Chief Executive Officer, Experimentica Ltd
    Giedrius Kalesnykas

    Dr. Kalesnykas earned his Ph.D. in Neuroscience in 2005 from the University of Kuopio, Finland, and completed several postdoctoral fellowships studying the pathophysiology of glaucoma and ocular gene therapy. In 2009, Dr. Kalesnykas was awarded the prestigious position of Finnish Academy Research Fellow, which he held until 2013. He was a visiting researcher at the Wilmer Eye Institute at The Johns Hopkins University in 2010-2011. In 2013, he founded Experimentica Ltd., which under his leadership has grown to become one of the leading preclinical CROs dedicated to drug discovery and development for ophthalmic disorders.

    James Arps

    Director, ProMed Pharma
    James Arps

    Jim has over 20 years of experience managing product development and commercialization of medical devices, advanced coatings, and drug delivery technology. He has worked with both industry and academic partners, guiding products through all stages of development from conceptualization through to customer release. At ProMed Pharma, he oversees program development activities for polymer-based drug releasing implants and combination device components, working with a team of engineers to develop new drug delivery vehicles as well as robust manufacturing processes and platforms for controlled release of drugs from a variety of materials for applications in cardiovascular, women’s health, and ophthalmology. He has a Ph.D. in Applied Physics from Vanderbilt University and an M.S. in Management of Technology from the University of Texas-San Antonio.

    Jinzhong Zhang

    Vice President, Graybug Vision Inc
    Jinzhong Zhang

    Michael Burr

    Vice President of Product Development, iVeena
    Michael Burr

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Mitchell De Long

    Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first FDA approval coming in 2017. Aerie has grown from the initial 3-person team to over 300 employees, and went public on NASDAQ in 2013, where its current valuation is over $2 billion (US). Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs to his credit.

    Naj Sharif

    Vice President, Santen Incorporated
    Naj  Sharif

    Naj Sharif, PhD, FARVO, FBPhS has >34-years’ pharmaceutical drug discovery research experience. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Travatan®, Patanol®, Emedine® to treat glaucoma/ocular hypertension and allergic conjunctivitis. He is currently a VP at Santen Inc where he recently helped acquire the PRESERFLO Microshunt. Dr. Sharif is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research, and the recipient of the “Sir James Black Award” for contributions to drug discovery. He is an Adjunct Professor at multiple universities and has published >205 scientific articles, edited 2 books and holds 24 issued US/EU patents.

    Parisa Zamiri

    Global Head of clinical development in Ophthalmology, Novartis Pharmaceutical inc
    Parisa Zamiri

    Peter Morgan Warren

    Medical Assessor, MHRA
    Peter Morgan Warren

    Peter Morgan Warren

    Medical Assessor, MHRA
    Peter Morgan Warren

    Dr Peter Morgan-Warren is a Medical Assessor at the Medicines & Healthcare products Regulatory Agency.
    After graduating in medicine from University of Oxford, Peter worked as a Medical Officer for the Royal Air Force, with clinical practice in both primary and secondary care and additional aviation medicine/administrative roles. He then went on to undertake specialist clinical training in ophthalmology in the West Midlands and was appointed as the inaugural Medical Research Council/Royal College of Ophthalmologists John Lee Fellow in 2012 for his doctoral research programme into the development of novel biotherapeutics for neuroprotection and regeneration for optic neuropathy. He was awarded his PhD from University of Birmingham in 2016.
    Peter is now a Medical Assessor at the MHRA, involved in the review and assessment of regulatory submission for national and European medicinal products, and contribution to scientific advice provision for clinical development programmes.
     

    Raid Alany

    Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University
    Raid Alany

    Sahar Awwad

    CSO, Optceutics Ltd
    Sahar Awwad

    Dr Sahar Awwad is the co-founder and Chief Scientific Officer (CSO) of Optceutics Ltd and also a Postdoctoral Research Fellow in UCL School of Pharmacy, UCL Institute of Ophthalmology and National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). Dr Awwad has more than 10 years experience in biologics and small molecule drug development and delivery, ocular drug delivery and pharmaceutical technology. Dr Awwad drives translational pharmaceutics research in affinity-based drug delivery, novel formulation strategies to extend drug release and modelling ocular pharmacokinetics.

    Steve Brocchini

    Academic Staff , UCL School of Pharmacy and UCL Institute of Ophthalmology
    Steve Brocchini

    Virginia Calder

    Senior Lecturer, Ocular Biology, Ucl Hospitals
    Virginia Calder

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology
    Virginia Calder

    Professor Calder is an immunologist with over 30 years’ experience in inflammatory eye disease research. It is well-known that immunosuppressives can be effective in arresting intraocular immune-mediated diseases but their associated side-effects can be devastating, especially for the eye, when taken long term. The focus of her team is to investigate the underlying immune mechanisms and potential novel therapeutic targets in chronic inflammatory eye diseases such as posterior uveitis, as well as blepharo, atopic and vernal keratoconjunctivitis. This involves utilizing relevant experimental models of disease and validating results with clinically well-defined donor specimens, including conjunctival tissues, aqueous humor, tear fluid, peripheral blood and serum. She has considerable expertise in determining the therapeutic efficacy of novel compounds in experimental disease models, as part of previous and ongoing research collaborations with Pharma.

    William Dallman

    Clinical Development Manager, Eyenuk
    William Dallman

    I have 10 years’ experience of Implementing and managing local Screening Programme’s within the English National Diabetic Eye Screening Programme. I am currently a National Grading College member and Professional Clinical Advisor for Public Health England’s External Quality Assurance Team. I hold a Diploma in Diabetic Retinopathy Screening, a BA (Hons) in Business Management and European Studies and I am currently completing a MSc in Health and Social Care Leadership.

    Sponsors

    Official Media Partner

    Key Media Partners

    Supporting Media Partners

    Supporters

    Workshops

    Ophthalmic Drugs Focus Day
    Workshop

    Ophthalmic Drugs Focus Day

    Copthorne Tara Hotel
    18th November 2019
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Attendee list 2019

    Download

    Interview with Che Connon, Newscastle University

    Download

    Interview with Sahar Awwad

    Download

    Ophthalmic Drugs Chair Letter 2019

    Download

    Andrew Radin Interview

    Download

    Interview with Mitchell de Long

    Download

    2018 Infographic

    Download

    Standardized Mobility Testing for Assessment of Functional Vision

    Download

    Standarization and Validation of Functional Read-Outs in Preclinical Ocular Models

    Download

    New Ophthalmic Drug Delivery Technologies

    Download

    Global Reimbursement Strategies in Ophthalmic Clinical Development

    Download

    Interview with Michael Burr from Iveena

    Download

    2019 Conference Programme

    Download

    2019 Speaker List

    Download

    Ophthalmic Drugs 2019 Conference Brochure

    Download

    Focus Day Programme

    Download

    2018 Ophthalmic Drugs Attendees

    Download

    Sponsors


    Experimentica

    Sponsors
    http://www.experimentica.com

    Experimentica Ltd. is a global company and the largest ophthalmic CRO in Northern Europe, striving to provide scientific excellence by relying entirely on in-house expertise. Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland, Chicago, IL, USA, Shanghai, China, and R&D site in Vilnius, Lithuania. For more information, visit www.experimentica.com.


    ProMed Pharma

    Sponsors
    http://www.promedpharmallc.com

    ProMed Pharma specializes in the molding of drug-loaded silicones and thermoplastics and leverages this expertise to manufacture long-term implants and combination devices under cGMP. Working with established and early stage companies, we utilize robust manufacturing processes for controlled release of APIs utilizing a variety of materials. From clinical trial materials to commercial products, ProMed supports pharmaceutical and medical device companies developing controlled release formulations including subcutaneous, orthopedic, cardiovacular, and ophthalmic implants, intravaginal rings, and steroid-eluting components. Please visit www.promedpharmallc.com for more details.

    Media Partners


    touchOPHTHALMOLOGY

    Official Media Partner
    http://www.touchophthalmology.com/

    touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content. touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content.

    Media Partners


    Gene Therapy Net

    Key Media Partners
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines

    Media Partners


    Pharma network magazine

    Supporting Media Partners
    https://www.pharmanetwork.digital

    PHARMAnetwork is a company specialized in publishing for the pharmaceutical industry. PHARMAnetwork has developed publications for CMO, CDMO and professionals working in the life sciences. PHARMAnetwork designs specialized studies for pharmaceutical companies, contract service providers and investment firms. PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry. We perform interviews and write articles whose thematic strategies, organizations, mergers and acquisitions, regulatory, innovation in the pharmaceutical development and contract manufacturing. https://www.pharmanetwork.digital


    IPI

    Supporting Media Partners
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    ONdrugDelivery Magazine

    Supporting Media Partners
    http://ondrugdelivery.com

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    World Pharma News

    Supporting Media Partners
    http://www.worldpharmanews.com/



    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    Media Partners


    eyetube

    Supporters
    http://eyetube.net

    Eyetube.net is ophthalmology’s leading source for high-quality, full-narrated ophthalmic surgical videos. The Web site was created by a panel of experts to better educate ophthalmologists through the online archiving and sharing of videos. Our mission is to foster a secure, engaging physician community across all sub-specialties powered by user-generated content, whether it be videos, discussion threads, or blogs.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out